Cargando…
Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States
BACKGROUND: Migraine is a common neurological disease that can have a substantial impact on patients’ lives and on society. Erenumab, a fully human monoclonal antibody that targets the calcitonin gene-related peptide receptor, was specifically developed for migraine prevention. The efficacy of erenu...
Autores principales: | Tepper, Stewart J, Fang, Juanzhi, Zhou, Lujia, Shen, Ying, Vo, Pamela, Abdrabboh, Ahmad, Glassberg, Mrudula B, Ferraris, Matias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394219/ https://www.ncbi.nlm.nih.gov/pubmed/33998825 http://dx.doi.org/10.18553/jmcp.2021.21060 |
Ejemplares similares
-
Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study
por: Tepper, Stewart J., et al.
Publicado: (2021) -
Cognitive effects of onabotulinumtoxinA in chronic migraine
por: Ho, Susan, et al.
Publicado: (2020) -
OnabotulinumtoxinA: Still the Present for Chronic Migraine
por: Baraldi, Carlo, et al.
Publicado: (2023) -
Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety
por: Blumenfeld, Andrew M, et al.
Publicado: (2019) -
Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients
por: Eren, Ozan E., et al.
Publicado: (2020)